In a report released today, Andrew Mok CFA from Barclays maintained a Buy rating on HCA Healthcare, with a price target of $445.00. The company’s shares closed yesterday at $426.27.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Mok CFA is an analyst with an average return of -1.9% and a 51.69% success rate. Mok CFA covers the Healthcare sector, focusing on stocks such as HCA Healthcare, Humana, and UnitedHealth.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for HCA Healthcare with a $412.13 average price target, implying a -3.32% downside from current levels. In a report released yesterday, KeyBanc also maintained a Buy rating on the stock with a $465.00 price target.
Based on HCA Healthcare’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $18.61 billion and a net profit of $1.65 billion. In comparison, last year the company earned a revenue of $17.49 billion and had a net profit of $1.46 billion
Read More on HCA:
Disclaimer & DisclosureReport an Issue
- HCA Healthcare price target raised to $465 from $370 at KeyBanc
- HCA Healthcare price target raised to $412 from $375 at Wells Fargo
- Nutex Health appoints Wesley Bamburg as COO
- HCA Healthcare price target raised to $445 from $390 at Barclays
- HCA Healthcare price target raised to $430 from $375 at BofA
/Unitedhealth%20Group%20Inc%20HQ%20photo-by%20jetcityimage%20via%20iStock.jpg)
/Advanced%20Micro%20Devices%20Inc_%20logo%20and%20chart%20data-by%20Poetra_%20RH%20via%20Shutterstock.jpg)
/NVIDIA%20Corp%20logo%20on%20phone-by%20Evolf%20via%20Shutterstock.jpg)
/Apple%20products%20on%20desk%20by%20Ake%20Ngiamsanguan%20via%20iStock.jpg)
